Operating Income
Operating Income
Regeneron Pharmaceuticals Operating Income decreased by 26.9% to $642.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.7%, from $591.70M to $642.90M. Over 4 years (FY 2021 to FY 2025), Operating Income shows a downward trend with a -20.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Income
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
Growth in operating income suggests that the core business is becoming more profitable and efficient.
Detailed definition
The profit realized from a business's own operations after deducting operating expenses like wages, depreciation, and co...
Peer comparison
This is a key metric for comparing the fundamental business performance of companies with different tax or debt structures.
Metric ID:
is_operating_incomeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.35B | $1.85B | $2.64B | $1.26B | $1.11B | $1.22B | $1.15B | $946.70M | $1.02B | $1.11B | $972.90M | $751.40M | $1.07B | $1.18B | $990.20M | $591.70M | $1.08B | $1.03B | $879.90M | $642.90M |
| QoQ Change | — | -44.8% | +42.9% | -52.3% | -11.8% | +10.3% | -6.3% | -17.4% | +7.4% | +9.3% | -12.4% | -22.8% | +42.3% | +10.3% | -16.0% | -40.2% | +82.4% | -4.9% | -14.3% | -26.9% |
| YoY Change | — | — | — | — | -66.8% | -33.8% | -56.6% | -24.8% | -8.4% | -9.2% | -15.2% | -20.6% | +5.2% | +6.2% | +1.8% | -21.3% | +0.9% | -12.9% | -11.1% | +8.7% |
Range$591.70M – $3.35B
CAGR-29.3%
Avg YoY Growth-16.1%
Median YoY Growth-12.0%
Current Streak3 quarters decline
Operating Income at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's operating income?
- Regeneron Pharmaceuticals (REGN) reported operating income of $642.90M in Q1 2026.
- How has Regeneron Pharmaceuticals's operating income changed year-over-year?
- Regeneron Pharmaceuticals's operating income increased by 8.7% year-over-year, from $591.70M to $642.90M.
- What is the long-term trend for Regeneron Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's operating income has grown at a -20.5% compound annual growth rate (CAGR), from $8.95B to $3.58B.
- What does operating income mean?
- The profit earned from core business activities, before accounting for interest and taxes.